Thymoma needs a new staging system

Hisao Asamura, Kazuo Nakagawa, Yoshihiro Matsuno, Kenji Suzuki, Shun Ichi Watanabe, Ryosuke Tsuchiya

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Despite the wide use of the Masaoka staging system for thymoma, the distribution of survival by stage group is not well balanced. The new staging systems for testing were defined as follows: stage I was created by merging Masaoka's stages I and II, and stage IV remained unchanged. Stages II and III were defined as thymomas with invasive growth and the following combinations of tumor diameter and number of involved structures/organs. Scheme 1: stage II included tumors less than 10 cm in diameter and involving one neighboring structure/organ. Stage III included tumors with all combinations of diameter and number of involved structures/organs other than those in stage II. Scheme 2: stage II included tumors of all combinations other than those in stage III. Stage III included tumors 10 cm or more in diameter and involving two or more structures/organs. The survival curves were assessed for 138 patients treated at the National Cancer Center, Tokyo. The 10-year survival rates for each stage according to the Masaoka, Scheme 1, and Scheme 2 systems were as follows: stage I (100%, 100%, 100%), stage II (100%, 86%, 83%), stage III (70%, 64%, 34%), and stage IV (34%, 34%, 34%), respectively. The survival curves for Scheme 1 gave the most balanced distribution of survival in each staging group. By considering both tumor diameter and number of involved structures/organs, Masaoka's stages I-III could be rearranged with more balanced distribution of survival.

Original languageEnglish
Pages (from-to)163-167
Number of pages5
JournalInteractive Cardiovascular and Thoracic Surgery
Volume3
Issue number1
DOIs
Publication statusPublished - 2004 Mar
Externally publishedYes

Fingerprint

Thymoma
Survival
Neoplasms
Tokyo
Survival Rate
Growth

Keywords

  • Mediastinal tumor
  • Pathology
  • Surgery
  • Thymectomy
  • Thymoma

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine
  • Surgery

Cite this

Asamura, H., Nakagawa, K., Matsuno, Y., Suzuki, K., Watanabe, S. I., & Tsuchiya, R. (2004). Thymoma needs a new staging system. Interactive Cardiovascular and Thoracic Surgery, 3(1), 163-167. https://doi.org/10.1016/S1569-9293(03)00265-2

Thymoma needs a new staging system. / Asamura, Hisao; Nakagawa, Kazuo; Matsuno, Yoshihiro; Suzuki, Kenji; Watanabe, Shun Ichi; Tsuchiya, Ryosuke.

In: Interactive Cardiovascular and Thoracic Surgery, Vol. 3, No. 1, 03.2004, p. 163-167.

Research output: Contribution to journalArticle

Asamura, H, Nakagawa, K, Matsuno, Y, Suzuki, K, Watanabe, SI & Tsuchiya, R 2004, 'Thymoma needs a new staging system', Interactive Cardiovascular and Thoracic Surgery, vol. 3, no. 1, pp. 163-167. https://doi.org/10.1016/S1569-9293(03)00265-2
Asamura, Hisao ; Nakagawa, Kazuo ; Matsuno, Yoshihiro ; Suzuki, Kenji ; Watanabe, Shun Ichi ; Tsuchiya, Ryosuke. / Thymoma needs a new staging system. In: Interactive Cardiovascular and Thoracic Surgery. 2004 ; Vol. 3, No. 1. pp. 163-167.
@article{40e0d5e10cb2498a8909091dc5106773,
title = "Thymoma needs a new staging system",
abstract = "Despite the wide use of the Masaoka staging system for thymoma, the distribution of survival by stage group is not well balanced. The new staging systems for testing were defined as follows: stage I was created by merging Masaoka's stages I and II, and stage IV remained unchanged. Stages II and III were defined as thymomas with invasive growth and the following combinations of tumor diameter and number of involved structures/organs. Scheme 1: stage II included tumors less than 10 cm in diameter and involving one neighboring structure/organ. Stage III included tumors with all combinations of diameter and number of involved structures/organs other than those in stage II. Scheme 2: stage II included tumors of all combinations other than those in stage III. Stage III included tumors 10 cm or more in diameter and involving two or more structures/organs. The survival curves were assessed for 138 patients treated at the National Cancer Center, Tokyo. The 10-year survival rates for each stage according to the Masaoka, Scheme 1, and Scheme 2 systems were as follows: stage I (100{\%}, 100{\%}, 100{\%}), stage II (100{\%}, 86{\%}, 83{\%}), stage III (70{\%}, 64{\%}, 34{\%}), and stage IV (34{\%}, 34{\%}, 34{\%}), respectively. The survival curves for Scheme 1 gave the most balanced distribution of survival in each staging group. By considering both tumor diameter and number of involved structures/organs, Masaoka's stages I-III could be rearranged with more balanced distribution of survival.",
keywords = "Mediastinal tumor, Pathology, Surgery, Thymectomy, Thymoma",
author = "Hisao Asamura and Kazuo Nakagawa and Yoshihiro Matsuno and Kenji Suzuki and Watanabe, {Shun Ichi} and Ryosuke Tsuchiya",
year = "2004",
month = "3",
doi = "10.1016/S1569-9293(03)00265-2",
language = "English",
volume = "3",
pages = "163--167",
journal = "Interactive Cardiovascular and Thoracic Surgery",
issn = "1569-9293",
publisher = "European Association for Cardio-Thoracic Surgery",
number = "1",

}

TY - JOUR

T1 - Thymoma needs a new staging system

AU - Asamura, Hisao

AU - Nakagawa, Kazuo

AU - Matsuno, Yoshihiro

AU - Suzuki, Kenji

AU - Watanabe, Shun Ichi

AU - Tsuchiya, Ryosuke

PY - 2004/3

Y1 - 2004/3

N2 - Despite the wide use of the Masaoka staging system for thymoma, the distribution of survival by stage group is not well balanced. The new staging systems for testing were defined as follows: stage I was created by merging Masaoka's stages I and II, and stage IV remained unchanged. Stages II and III were defined as thymomas with invasive growth and the following combinations of tumor diameter and number of involved structures/organs. Scheme 1: stage II included tumors less than 10 cm in diameter and involving one neighboring structure/organ. Stage III included tumors with all combinations of diameter and number of involved structures/organs other than those in stage II. Scheme 2: stage II included tumors of all combinations other than those in stage III. Stage III included tumors 10 cm or more in diameter and involving two or more structures/organs. The survival curves were assessed for 138 patients treated at the National Cancer Center, Tokyo. The 10-year survival rates for each stage according to the Masaoka, Scheme 1, and Scheme 2 systems were as follows: stage I (100%, 100%, 100%), stage II (100%, 86%, 83%), stage III (70%, 64%, 34%), and stage IV (34%, 34%, 34%), respectively. The survival curves for Scheme 1 gave the most balanced distribution of survival in each staging group. By considering both tumor diameter and number of involved structures/organs, Masaoka's stages I-III could be rearranged with more balanced distribution of survival.

AB - Despite the wide use of the Masaoka staging system for thymoma, the distribution of survival by stage group is not well balanced. The new staging systems for testing were defined as follows: stage I was created by merging Masaoka's stages I and II, and stage IV remained unchanged. Stages II and III were defined as thymomas with invasive growth and the following combinations of tumor diameter and number of involved structures/organs. Scheme 1: stage II included tumors less than 10 cm in diameter and involving one neighboring structure/organ. Stage III included tumors with all combinations of diameter and number of involved structures/organs other than those in stage II. Scheme 2: stage II included tumors of all combinations other than those in stage III. Stage III included tumors 10 cm or more in diameter and involving two or more structures/organs. The survival curves were assessed for 138 patients treated at the National Cancer Center, Tokyo. The 10-year survival rates for each stage according to the Masaoka, Scheme 1, and Scheme 2 systems were as follows: stage I (100%, 100%, 100%), stage II (100%, 86%, 83%), stage III (70%, 64%, 34%), and stage IV (34%, 34%, 34%), respectively. The survival curves for Scheme 1 gave the most balanced distribution of survival in each staging group. By considering both tumor diameter and number of involved structures/organs, Masaoka's stages I-III could be rearranged with more balanced distribution of survival.

KW - Mediastinal tumor

KW - Pathology

KW - Surgery

KW - Thymectomy

KW - Thymoma

UR - http://www.scopus.com/inward/record.url?scp=1842736358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842736358&partnerID=8YFLogxK

U2 - 10.1016/S1569-9293(03)00265-2

DO - 10.1016/S1569-9293(03)00265-2

M3 - Article

C2 - 17670205

AN - SCOPUS:1842736358

VL - 3

SP - 163

EP - 167

JO - Interactive Cardiovascular and Thoracic Surgery

JF - Interactive Cardiovascular and Thoracic Surgery

SN - 1569-9293

IS - 1

ER -